Intended for UK patients and members of the public
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 14 Nov 2025
Description of update: To update sections 4.3, 4.4, 4.5 & 4.8 of the SmPC and sections 2 & 4 of PIL in line with the information of Reference product Cytarabine 100 mg/ml Solution for Injection; National authorisation number: PA0822/200/002; MAH: Pfizer Healthcare Ireland). To update section 4.3 and 4.6 of SmPC and section 2 of PIL information leaflet with the contraception duration for men and women as per the SWP recommendation.
Date of approval: 01/10/2025
SmPC sections updated: 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 5.3 and 10
Last updated on this site: 14 Nov 2025
Description of update: To update sections 4.3, 4.4, 4.5 & 4.8 of the SmPC and sections 2 & 4 of PIL in line with the information of Reference product Cytarabine 100 mg/ml Solution for Injection; National authorisation number: PA0822/200/002; MAH: Pfizer Healthcare Ireland). To update section 4.3 and 4.6 of SmPC and section 2 of PIL information leaflet with the contraception duration for men and women as per the SWP recommendation.
Date of approval: 01/10/2025
PIL sections updated: 2, 3, 4 and 6
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintFor any further assistance, please get in touch.